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BACKGROUND: To optimise predictive models for sentinal node biopsy (SNB) positivity, relapse and survival, using clinico-pathological
characteristics and osteopontin gene expression in primary melanomas.
METHODS: A comparison of the clinico-pathological characteristics of SNB positive and negative cases was carried out in 561 melanoma
patients. In 199 patients, gene expression in formalin-fixed primary tumours was studied using Illumina’s DASL assay. A cross validation
approach was used to test prognostic predictive models and receiver operating characteristic curves were produced.
RESULTS: Independent predictors of SNB positivity were Breslow thickness, mitotic count and tumour site. Osteopontin expression best
predicted SNB positivity (P¼ 2.4 107), remaining significant in multivariable analysis. Osteopontin expression, combined with
thickness, mitotic count and site, gave the best area under the curve (AUC) to predict SNB positivity (72.6%). Independent predictors
of relapse-free survival were SNB status, thickness, site, ulceration and vessel invasion, whereas only SNB status and thickness predicted
overall survival. Using clinico-pathological features (thickness, mitotic count, ulceration, vessel invasion, site, age and sex) gave a better
AUC to predict relapse (71.0%) and survival (70.0%) than SNB status alone (57.0, 55.0%). In patients with gene expression data, the
SNB status combined with the clinico-pathological features produced the best prediction of relapse (72.7%) and survival (69.0%),
which was not increased further with osteopontin expression (72.7, 68.0%).
CONCLUSION: Use of these models should be tested in other data sets in order to improve predictive and prognostic data for patients.
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Several clinico-pathological characteristics of primary melanoma
have been identified as independent prognostic factors for relapse
and overall survival (OS), including age, sex, tumour site, Breslow
thickness, ulceration, mitotic count, vessel invasion, regression and
the presence of tumour-infiltrating lymphocytes (TILs) (Johnson
et al, 1985; Clark et al, 1989; Cochran et al, 2000; Balch et al, 2001).
Although as yet no OS benefit has been demonstrated from sentinal
node biopsy (SNB) (Morton et al, 2006), the SNB status has been
determined to be the single most important prognostic factor for
melanoma (Gershenwald et al, 1999; Ferrone et al, 2002; Gutzmer
et al, 2008) and is used in the American Joint Committee on Cancer
(AJCC) staging system for cutaneous melanoma.
Breslow thickness is usually used to identify patients for SNB,
but it has been shown to have poor sensitivity and specificity in
predicting positivity (Sondak et al, 2004). Several groups have
attempted to identify predictors of SNB positivity using clinical
and histological characteristics of the primary melanoma, but so far
only thickness has been consistently identified (Sondak et al, 2004),
and it therefore remains the most commonly used criterion
in selecting patients for SNB. If SNB is limited to melanoma
patients with a tumour thickness X1mm, then micrometastases
(SNB positivity) are detected in around 24% (Lens et al, 2002). The
purpose of this study was to identify characteristics of primary
melanoma, which better predict SNB positivity; to identify
predictors of relapse-free survival (RFS) and OS and also to
identify genetic prognostic biomarkers allowing further insight
into the biological pathways important in melanoma progression.
We have used Illumina’s DASL (cDNA-mediated annealing,
selection, extension and ligation) assay (Illumina, Service XS,
Leiden, Netherlands) to investigate prognostic biomarkers in
formalin-fixed paraffin-embedded (FFPE) primary melanomas.
This is a novel assay designed specifically to generate reproducible
RNA profiles from FFPE tissue, in which the extracted RNA is
often significantly degraded: partially degraded RNA has breaks
throughout the RNA transcript making it difficult to generate high-
quality full-length cDNA. The DASL assay uses random priming
during cDNA synthesis, which means it does not depend on an
intact poly-A tail, and in addition it only requires the probes to
span about 50 bases and is therefore adapted to degraded RNA
(Illumina, 2005a, b). Gene expression studies in FFPE melanomas
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have been relatively few in number, and most studies have
predominantly used immunohistochemical staining and polymer-
ase chain reaction techniques, allowing only a few genes to be
analysed at a time. More recently, Winnepenninckx et al (2006)
identified a 254-gene signature predictive of survival in 83
cryopreserved primary tumours, and Kauffmann et al (2008)
identified increased expression of DNA repair genes in metastatic
melanoma tumours from 60 tumour samples. Two small previous
studies using cryopreserved tumours also showed a correlation
between osteopontin expression and progression in melanoma
(Zhou et al, 2005; Jaeger et al, 2007). We have recently reported the
successful use of the DASL assay in melanoma primaries (Conway
et al, 2009).
MATERIALS AND METHODS
Patients with melanomas of Breslow thickness X0.75mm having
undergone SNB were recruited to a multicentre retrospective
study. A cutoff of 0.75mm rather than 1mm was chosen, as we
were aware that participating centres had historically carried out
SNBs for o1mm melanomas based on other histological criteria,
such as vertical growth phase, Clark’s level IV/V and regression.
The study was approved both by the UK national ethics
committees (MREC: multicentre research ethics committee and
PIAG: patient information advisory group), which determined that
patients still under follow-up at the cancer centre should be
consented to use of their tissues. Five centres from the United
Kingdom (St George’s Hospital, London; Royal Surrey County
Hospital, Guildford; Southampton General Hospital, Southampton;
Castle Hill Hospital, Hull and St James’s University Hospital,
Leeds) identified all patients having had SNB in their departments
from November 1994 until 2006. The first 400 patients to have a
positive SNB were selected. As more patients undergoing SNB have
a negative than a positive SNB result, a subset of SNB-negative
patients were randomly selected, frequency matched by year of
SNB and by the centre at which the SNB was performed. Patients
were excluded if they had previous cancers other than non-
melanoma skin cancer or cervical carcinoma in situ or if they had
multiple melanoma primaries. Sample size calculations based on
250 patients in each group showed that the minimum detectable
odds ratio (OR) for predicting SNB positivity would be 2.2, with a
power of 80% and a significance level of 0.001 assuming a risk
factor prevalence of 0.4 and based on 50 independent factors being
analysed to produce a study-wide significance level of 0.05.
Clinico-pathological characteristics were extracted from clinical
files: age, sex, site of primary tumour, clinical maximal diameter of
tumour as measured macroscopically by the pathologist, Breslow
thickness, Clark’s level, histological subtype, mitotic count
(mm2), presence or absence of ulceration, regression, vessel
invasion, perineural invasion, TILs and microsatellites in either the
primary or wider excision. In a proportion of the cases, factors
such as ulceration (21.6%), regression (19.6%), vessel invasion
(30.3%), perineural invasion (59.9%) and microsatellites (57.3%)
were not mentioned in histology reports and were assumed to be
absent for purpose of analysis. A sensitivity analysis on the
completed data set for these five factors showed quantitatively
similar results. Follow-up data were similarly extracted from
clinical files. The date of first relapse in any site (local, in-transit,
regional or distal) was used to calculate RFS. Relapse-free survival
and OS were calculated from the date of primary diagnosis to time
point of the recurrence or death or last follow-up.
Tissue sampling/gene expression methods
Two hundred patients with a positive SNB who were first to
undergo the procedure were identified, and the stored FFPE
primaries were sought. We then randomly selected 100 of the
patients with a negative SNB, from groups matched by SNB year,
centre and sex, and their primary tumour blocks were also traced. A
tissue microarray needle was then used to sample the advancing edge
of the tumour (containing the lowest admixture of inflammatory or
stromal cells) horizontally producing a 0.8mm core of tumour as
described previously (Conway et al, 2009). RNA was extracted from
these tumour cores using the protocol in the High Pure Paraffin RNA
Kit (Roche Diagnostics Ltd, Burges Hill, UK) and supplied to a service
provider for gene expression studies using the Illumina DASL Cancer
Panel, which targets 502 cancer genes with unique probes in three
different locations per gene (Illumina, 2005b). Use of this technique
by our group and the quality control measures used are described
elsewhere (Conway et al, 2009).
Statistical methodology
Predictors of SNB positivity, RFS and OS were identified by
univariable and multivariable analyses using STATA version 9
(StataCorp 2007, College Station, TX, USA). Breslow thickness was
examined as a categorical variable using the same classification as
the AJCC staging system (Balch et al, 2003). Mitotic count was
classified as absent, low (1–6mm2) or high (46mm2) (Elder
and Murphy, 1991). Tumour sites were grouped into four, as arms,
head and neck, legs or trunk. Age and clinical diameter of the
primary melanoma were analysed as continuous variables. For
associations with SNB positivity, continuous variables were
analysed using t-tests and categorical variables using w2 con-
tingency table tests. Simple logistic regression was used to obtain
ORs and 95% confidence intervals (CIs). The determinants of RFS
and OS were identified using Cox’s proportional hazards model to
give hazard ratios (HR) and 95% CI. Multiple forward and
backward stepwise logistic regression analyses were then per-
formed to identify independent predictors of SNB positivity, RFS
and OS. A significance level of Po0.05 was used.
The gene expression data were normalised within BeadStudio
Gene Expression Module v3.4 (Illumina, San Diego, CA, USA)
before exporting to STATA version 9 for statistical analyses.
Fluorescence intensities from Cy3 and Cy5 dyes were averaged for
each probe and the expression level of each gene was computed as
an average of the intensities from three probes. Background
correction and cubic B-spline smoothing methods (Workman et al,
2002) were used and sample scaling was applied to remove the
variation between plates. Samples that failed to express over 250
genes were classified as failed and excluded from further analysis.
Mean gene expression was calculated for the sample replicates.
Expression of each gene was transformed to a log2 scale so that an
increase of one unit corresponds to a doubling of expression levels;
comparison between samples categorised by histological variables
was carried out using two-sample t-tests and regression. Survival
analysis was performed using a separate Cox’s proportional
hazards model for each gene. Using a Bonferroni correction for
multiple testing, the significance level was set at 0.0001 for these
univariable analyses.
A cross-validation approach implemented in R (version 2.8.0.)
(Team, 2010) was used to estimate the predictive ability of the
different prognostic models. Ten percent of the data were
excluded, the model fitted to the remaining 90% and the predictive
ability of this model on the excluded 10% was evaluated. This
process was repeated 1000 times, excluding a random 10% each
time, and the results were averaged.
RESULTS
A combined total of 2044 sentinel node biopsies were carried out
in the five participating centres, and 439 patients had a positive
result (21.5%). From initial lists provided by the five centres,
previously recorded data on Breslow thickness was available in
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1570 patients (70%). Overall, 320 patients (20%) had an SNB
carried out for a melanoma o1mm, and from this group,
24 patients (7.5%) had a positive SNB.
After identification of SNB positive and negative patients as
described above, a total of 701 patients’ case notes were reviewed,
of whom 608 patients met the inclusion criteria. Of these 608
patients, 2 refused participation in the study and 45 did not reply
to the invitation to participate, leaving 561 patients’ data sets
available for analysis. The majority of these patients (73%) were
recruited from St George’s Hospital, Melanoma Unit London,
where SNB had been carried out for the longest period. In total,
218 FFPE primary tumours were collected. Of these, 199 blocks
were selected for sampling. Reasons for not sampling a block included
too little residual tumour after sectioning for clinical purposes or other
research projects, tumour cells being mixed with large numbers of
normal stromal or inflammatory cells, or because the wrong blocks
were sent. Only two (0.9%) of the extracted samples were classified as
failed samples. One of these failed samples was a technical replicate,
which left 198 tumour samples for analysis. The mean age of the
blocks was 6.26 years (range 2.23–15.16 years). Increasing age of block
was associated with decreased gene detection (Spearman’s correlation
0.24, P¼ 0.0002) (Conway et al, 2009).
Table 1 shows the clinico-pathological characteristics of the
patients in the total study group and in the tumour subset. Owing
to the selection process, sentinel lymph nodes were positive for
tumours in 286 of 561 patients (51.0%) in the total study group and
in 131 of 198 patients whose FFPE tumours were sampled (66.2%)
(the tumour subset). In our study group, there were 68 patients
with a Breslow thickness between 0.75 and 1mm (14 had a positive
SNB, 20.6%). The median follow-up time for the total study group
was 29.5 and 38.4 months for the tumour subset.
Prediction of SNB status
Clinico-pathological predictors of SNB positivity Table 2 shows
the results of univariable unadjusted w2 analysis and age/sex-
adjusted logistic regression analysis of clinico-pathological
factors associated with SNB positivity. In single variable analyses,
the clinico-pathological factors associated with an increased
risk of SNB positivity were increasing Breslow thickness (overall
w2, P¼o0.0001), Clark’s level (overall w2, P¼ 0.001), higher
mitotic count (overall w2, Po0.0001), presence of ulceration
(P¼o0.0001), presence of vessel invasion (P¼ 0.02), presence of
microsatellites (P¼ 0.007), tumour site (overall w2, P¼ 0.04) and
histological subtype (overall w2, P¼ 0.005). Patients with tumours
situated on the leg or trunk showed a higher risk of SNB positivity
than those with tumours on the arm (P¼ 0.02, 0.007, respectively).
Patients with nodular melanomas showed a higher risk of SNB
positivity compared with patients with superficial spreading
melanomas (P¼ 0.02). Factors associated with a decreased risk
of SNB positivity were the presence of more TILs (P¼ 0.04) and
the presence of regression (P¼ 0.05). Factors not found to be
significantly associated with SNB positivity were age, sex, peri-
neural invasion and clinical diameter of the primary melanoma.
Clark’s level and histological subtype were mentioned in
histology reports less frequently than other variables, indicating
higher amounts of missing data. These variables were therefore not
included in the multivariable analyses. However, both Clark’s level
and histological subtype showed a strong correlation with Breslow
thickness (Spearman’s correlation 0.4, Po0.00001), and in the
subset of individuals without missing data they were not
independently significantly associated with SNB positivity once
adjustment was made for Breslow thickness alone. The remaining
significant prognostic factors adjusting for age and sex were
entered into a stepwise logistic regression model, which revealed
that the independent predictors of SNB positivity were thickness,
mitotic count and tumour site (Table 3). The results were the same
using either forwards or backwards selection.
DASL gene expression data and prediction of SNB
positivity
The gene whose expression was most predictive of SNB positi-
vity in univariable analysis in this study was osteopontin (SPP1),
(OR 2.7 for each doubling of expression levels, 95% CI (1.8–4.1),
P¼ 2.4 107). This was the only gene on the DASL cancer
panel to be significantly associated with SNB positivity following
Table 1 Clinico-pathological data in total study group and the subset of
patients in whom primary tumours were sampled
Variable
Total study
group
FFPE tumour
subset
Total number of patients 561 198
Number of patients with
positive SNB (%)
286 (51.0) 131 (66.2%)
Age at SNB years
(mean and range)a
51.4 (7.0–88.7) 52.2 (14.8–88.1)
Sex – male (number and %) 275 (49.0) 103 (52.0)
Site of tumour, number (%)
Arm 110 (19.6) 44 (22.2)
Head–neck 38 (6.8) 17 (8.6)
Leg 202 (36.0) 69 (34.9)
Trunk 211(37.6) 68 (34.3)
Breslow thickness, mm;
median (range)
1.9 (0.75–24) 2.00 (0.8–24.0)
Clark’s level, number (%)b
I/II/III 160 (33.1) 52 (31.1)
IV 290 (60.1) 100 (59.9)
V 33 (6.8) 15 (9.0)
Histological subtypeb
Superficial spreading 193 (52.3) 50 (42.4)
Nodular 132 (35.8) 54 (45.8)
Other 44 (11.9) 14 (11.8)
Mitotic count, number (%)b
o1 83 (18.8) 22 (12.2)
1–6 227 (51.3) 90 (50.0)
46 132 (29.9) 68 (37.8)
Ulcerated tumours, number (%)b 142 (25.7) 58 (29.3)
Presence of vessel invasion,
number (%)b
26 (4.7) 12 (6.1)
Presence of regression, number (%)b 73 (13.4) 18 (9.2)
Presence of perineural invasion,
number (%)b
6 (1.1) 2 (1.0)
Presence of microsatellites,
number (%)b
23 (4.2)
TILs, number (%)b
Absent 123 (25.0) 51 (27.9)
Non-brisk 264 (53.8) 90 (49.2)
Brisk 104 (21.2) 42 (22.9)
Median follow-up
time months (range)
29.5 (0.03–201) 38.4 (0.03– 111.7)
Number of relapsers (%) 126 (23.0) 63 (32.8)
Number of deaths (%) 83 (14.9) 47 (24.0)
Abbreviations: FFPE¼ formalin-fixed paraffin-embedded; SNB¼ sentinel node biopsy;
TIL¼ tumour-infiltrating lymphocyte. aOnly four patients under the age of 18 years
in study. bClarks level available for 483 patients, histological subtype available
for 369 patients, mitotic count available for 442 patients, ulceration available for
552 patients, vessel invasion available for 548 patients, regression available for
546 patients, perineural invasion available for 551 patients, microsatellites available
for 550 patients, TILs data available for 491 patients. Relapse status available in
548 patients, survival status available in 559 patients.
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Bonferroni correction. This association persisted in multivariable
analysis adjusting for age, sex and tumour site (OR 3.1, 95% CI
(2.0–4.8), P¼o0.0001), and when adjusted additionally for
thickness, mitotic count, presence of ulceration and vessel invasion
(OR 2.3, 95% CI (1.4–3.8), P¼ 0.001). The fold change of expres-
sion signal was 1.6 between negative and positive SNB patients in
unadjusted analysis. Osteopontin was also the gene most associated
with increasing tumour thickness (P¼ 3.15 1011, Spearman’s corre-
lation 0.42). It also showed significant association with increasing
mitotic count (P¼ 0.0009, Spearman’s correlation 0.24).
ROC analysis of models to predict SNB positivity
Using the total study group, we found that SNB positivity was best
predicted by a model including thickness, mitotic count, tumour
site, age and sex, giving an area under the curve (AUC) of 68.0%,
compared with using a model using thickness alone, which gave an
AUC of 58.0%. Figure 1 shows the receiver operating characteristic
(ROC) curves for prediction of SNB positivity if osteopontin is
included in the prognostic models using patients from the tumour
subset. Osteopontin expression gave a better AUC (65.7%) than
Breslow thickness alone (60.9%) in the tumour subset. Use of
clinico-pathological features (thickness, mitotic count, site, age
and sex) increased the AUC to 68.6%. However the best AUC of
72.6% was seen using a combination of osteopontin expression
and the clinico-pathological variables together.
Prognostic indicators
Clinico-pathological predictors of RFS and OS Univariable clinical
predictors of poor RFS included increasing age (HR 1.01 for each
year, 95% CI (1.00–1.03), P¼ 0.01), male sex (HR 1.6, 95% CI
(1.1–2.4), P¼ 0.007), increasing clinical diameter of the tumour
(HR 1.03, 95% CI (1.01–1.05), P¼o0.0001) and tumour site
(P¼ 0.007). Patients with tumours on the head and neck (HR 3.1,
95% CI (1.5–6.5), P¼ 0.003) and tumours on the trunk (HR 2.0,
95% CI (1.1–3.5), P¼ 0.02) were more likely to relapse than
patients with tumours on the arm. Histological predictors of
poorer RFS by univariable analysis included SNB positivity (HR
4.6, 95% CI (2.8–7.6), P¼o0.0001), increasing Breslow thickness
(Po0.0001), increasing mitotic count (P¼o0.0001), increasing
Clark’s level (P¼o0.0001), presence of ulceration (HR 2.7, 95% CI
(1.9–3.9), P¼o0.0001), presence of vessel invasion (HR 4.0, 95%
CI (2.2–7.1), P¼o0.0001) and the presence of microsatellites (HR
2.8, 95% CI (1.5–5.2), P¼ 0.001). Improved RFS was seen with a
brisk TILs reaction (HR 0.3, 95% CI (0.1–0.6), P¼ 0.001).
Univariable clinical predictors of poor OS were male sex (HR
1.8, 95% CI (1.1–2.8), P¼ 0.02), increasing tumour diameter
macroscopically (HR 1.04, 95% CI (1.02–1.06), P¼ 0.001) and
tumour site (P¼ 0.01). Patients with tumours on the trunk were
significantly less likely to survive than patients with tumours on
the arm (HR 2.8, 95% CI (1.3–5.9), P¼ 0.009). Histological
predictors of poorer OS by univariable analysis included SNB
positivity (HR 5.9, 95% CI (2.8–12.3), P¼o0.0001), increasing
Breslow thickness (Po0.0001), increasing mitotic count
(P¼o0.0001), increasing Clark’s level (P¼o0.0001), presence
Table 2 Clinico-pathological predictors of SNB positivity by univariable
unadjusted w2 analysis and age–sex-adjusted logistic regression analysis
Factor
Factor
groups
Overall v2
P-value
Adjusted for age and
sex OR (95% CI)*
Adjusted
P-value
Breslow (mm) 0.75–1 o0.0001 1.0
1.01–2 2.9 (1.5–5.5) 0.001
2.01–4 7.5 (3.8–14.7) o0.0001
44 9.9 (4.5–21.6) o0.0001
Clark’s level I/II/III 0.001 1.0
IV 1.5 (1.0–2.2) 0.04
V 5.7 (2.3–14.1) o0.0001
Mitoses (mm2) o1 o0.0001 1.0
1–6 3.5 (2.0–6.0) o0.0001
46 6.7 (3.6–12.4) o0.0001
Ulceration Absent o0.0001 1.0
Present 2.2 (1.5–3.3) o0.0001
Vessel invasion Absent 0.02 1.0
Present 2.7 (1.1–6.6) 0.03
Microsatellites Absent 0.007 1.0
Present 3.5 (1.3–9.5) 0.02
Tumour site Arm 0.04 1.0
Head/neck 1.5 (0.7–3.2) 0.3
Leg 1.9 (1.2–3.0) 0.01
Trunk 1.8 (1.1–2.9) 0.02
Tumour subtype SSM 0.005 1.0
Nodular 2.1 (1.3–3.3) 0.002
Other 1.0 (0.5–1.9) 1.0
TILs Absent 0.07 1.0
Non-brisk 0.9 (0.6–1.4) 0.7
Brisk 0.6 (0.3–1.0) 0.05
Regression Absent 0.06 1.0
Present 0.6 (0.4–1.0) 0.05
Abbreviations: CI¼ confidence interval; OR¼ odds ratio; SNB¼ sentinel node
biopsy; SSM¼ superficial spreading melanomas; TIL¼ tumour-infiltrating lymphocyte.
Table 3 Multivariable stepwise logistic regression analyses of clinico-
factors associated with SNB positivity, RFS and OS
Analysis Factor
Factor
groups
OR (95% CI) for
SNB positivity HR
(95% CI) for RFS/OS P-value
SNB
positivitya
Breslow
thickness (mm)
0.75–1 1.0
1.01–2 1.6 (0.7–3.5) 0.3
2.01–4 2.9 (1.3–6.9) 0.01
44 3.4 (1.3–9.3) 0.02
Mitotic
count (mm2)
0 1.0
0.1–6 2.7 (1.5–5.1) 0.002
46 4.2 (2.0–8.7) o0.0001
Tumour site Arm 1.0
Head/neck 1.9 (0.7–4.7) 0.2
Leg 2.4 (1.3–4.3) 0.005
Trunk 2.6 (1.4–4.8) 0.002
RFSb SNB status Negative 1.0
Positive 2.5 (1.5–4.3) 0.001
Breslow
thickness (mm)
0.75–1 1.0
1.01–2 2.2 (0.6–7.2) 0.2
2.01–4 2.2 (0.6–7.4) 0.2
44 5.3 (1.5–18.2) 0.009
Ulceration Absent 1.0
Present 1.6 (1.0–2.5) 0.03
Vessel invasion Absent 1.0
Present 3.0 (1.4–6.3) 0.003
Tumour site Arms 1.0
Legs 5.0 (2.0–12.5) 0.001
Head
and neck
1.5 (0.7–3.3) 0.3
Trunk 2.5 (1.2–5.2) 0.02
OSc SNB status Negative 1.0
Positive 4.6 (1.9–10.8) 0.001
Breslow
thickness (mm)
0.75–1 1.0
1.01–2 1.5 (0.3–6.5) 0.6
2.01–4 1.7 (0.4–7.4) 0.5
44 4.8 (1.1–21.1) 0.04
Abbreviations: CI¼ confidence interval; HR¼ hazards ratio; OR¼ odds ratio;
OS¼ overall survival; RFS¼ relapse-free survival; SNB¼ sentinel node biopsy;
TIL¼ tumour-infiltrating lymphocyte. aIncluded 408 patients in analysis, bIncluded
412 patients in analysis, cIncluded 409 patients in analysis.
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of ulceration (HR 2.4, 95% CI (1.5–3.8), P¼o0.0001), presence of
vessel invasion (HR 2.9, 95% CI (1.3–6.4), P¼ 0.01) and presence
of microsatellites (HR 3.3 95% CI (1.6–7.0), P¼ 0.001). Improved
OS was seen with a brisk TILs reaction (HR 0.3, 95% CI (0.1–0.8),
P¼ 0.02).
Clinical diameter of the lesion was not included in the
multivariable analysis of RFS and OS due to concerns about the
accuracy of measurement. The clinical diameter of the lesion
however showed strong correlation to Breslow thickness (Spear-
man’s correlation 0.3, Po0.00001) and did remain significant after
adjusting for Breslow thickness alone as a predictor of reduced
RFS and OS. Clark’s level was also once again not included in
multivariable analysis of RFS and OS due to missing data, but was
not significant as a predictor of reduced RFS or OS once
adjustment for Breslow thickness was made. Table 3 shows
multivariate stepwise logistic regression for RFS and OS showing
that the SNB status was the most significant single predictor of
both RFS and OS. Other independent predictors of RFS were
thickness, ulceration and vessel invasion. Breslow thickness was
also an independent predictor of OS.
Gene expression data and prognosis
Increased osteopontin expression was also associated with reduced
RFS (HR 1.6 for each doubling in expression levels, 95% CI (1.1–2.3),
P¼ 0.006) in unadjusted analyses, with a fold change of 1.32 between
relapsers and non-relapsers. Osteopontin expression remained
associated with RFS when corrected for age, sex and tumour site
(P¼ 0.006), but after adjusting additionally for SNB status did not
reach statistical significance at the P¼ 0.05 level (P¼ 0.07). It did
not remain significant in multivariable analysis with primary clinico-
pathological characteristics (thickness, mitotic count, ulceration, vessel
invasion) (Conway et al, 2009).
Increased osteopontin expression furthermore was associated
with poorer OS (HR 1.6, 95% CI (1.1–2.5), P¼ 0.02) in unadjusted
analysis. The fold change between survivors and non-survivors
was 1.3 (Conway et al, 2009). Osteopontin remained associated
with OS after adjusting for age, sex and tumour site (P¼ 0.02), but
did not remain significant (P¼ 0.07) after additionally adjusting
for SNB status. It did not remain significant in multivariable
analysis including primary clinico-pathological characteristics
(thickness, mitotic count, ulceration, vessel invasion).
ROC analysis of models to predict relapse and survival
Figure 2 shows the ROC curves of different prognostic models for
prediction of relapse (yes/no) for the total study group. A model
using SNB status alone gave an AUC of 57.0% for relapse and
55.0% for OS (not shown). The clinico-pathological model
(thickness, mitotic count, ulceration, vessel invasion, site, age
and sex) gave a better AUC of 71.0% for relapse and 70.0% for OS.
Combining this model with SNB status produced a small increase
to 76.0% for relapse and 74.0% for OS.
Figure 3 shows the ROC curves of different prognostic models to
predict relapse in the smaller tumour subset group. The AUC for
osteopontin expression combined with the clinico-pathological
features predicted relapse (67.4%) and survival (67.5%) better than
SNB status alone (53.7, 50.6%) or the clinico-pathological features
alone (66.1 and 67.0%). SNB status combined with the clinico-
pathological features produced a small increase to 72.7% for
relapse and 69.0% for survival prediction, which was not increased
further with osteopontin expression.
DISCUSSION
Several clinico-pathological characteristics have been inconsis-
tently associated with SNB positivity in a number of studies,
including Clark’s level, ulceration, mitotic count, microsatellites,
vessel invasion, TILs, tumour site and age (Mraz-Gernhard et al,
1998; Porter et al, 2000; Wagner et al, 2000; McMasters et al, 2001;
Nguyen et al, 2001; Rousseau et al, 2003; Sondak et al, 2004;
Kesmodel et al, 2005; Wong et al, 2005; Kruper et al, 2006; Paek
et al, 2007; Taylor et al, 2007; Pinero et al, 2008; Sartore et al,
2008). Although some previous studies have showed that patients
in younger age groups were more likely to have a positive sentinel
node (McMasters et al, 2001; Rousseau et al, 2003; Sondak et al,
2004; Paek et al, 2007), we found no association between age and
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Figure 2 Receiver operating characteristic (ROC) analysis of predictors
of relapse for the total study group. Blue: clinico-pathological features
(Breslow, mitotic count, vessel invasion, ulceration, site, age, sex) and SNB
status, AUC¼ 76.0%. Red: clinico-pathological features alone, AUC¼ 71.0%.
Black: SNB status alone, AUC¼ 57.0%.
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Figure 1 Receiver operating characteristic (ROC) analysis of predictors
of SNB positivity for tumour subset group. Green: Breslow, mitotic rate,
tumour site, age sex and SPP1 expression, AUC¼ 72.6%. Red: Breslow,
mitotic rate, tumour site, age and sex, AUC¼ 68.6%. Black: SPP1 expression
alone, AUC¼ 65.7%. Blue: Breslow thickness alone, AUC¼ 60.9%.
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SNB status in our study when analysing age as either a continous
or categorical variable (o50 or450 years). Variation in identified
predictors from previous studies may be due to small studies and
different study populations (Sondak et al, 2004; Wong et al, 2005).
In comparison with previous studies, our study has a large sample
size of SNB- positive patients and in addition has also looked at
gene expression in the primary melanoma to investigate prog-
nostic biomarkers.
In our study, the only clinico-pathological independent
predictors of SNB positivity were mitotic count, tumour site
and thickness. Although Breslow thickness is usually used alone
to identify patients eligible for SNB, we have shown that we
can predict positivity more effectively if we combine clinico-
pathological characteristics in a model, and therefore considering
these factors together would likely be more helpful in counselling
patients about SNB. Osteopontin gene expression was the only
gene on the DASL cancer panel to be significantly associated with
SNB positivity. By adding osteopontin expression to the clinico-
pathological model, the best AUC of 72.6% was achieved.
Osteopontin is a secreted phosphorylated glycoprotein also
known as secreted phosphoprotein-1 or SPP1. It was originally
identified as a bone matrix protein and subsequently identified as
a cytokine (Wang and Denhardt, 2008) and has been implicated in
the prognosis of different cancers, such as breast, lung, prostate,
colon, as well as melanoma (Rittling and Chambers, 2004;
Rangaswami et al, 2006). Several mechanisms by which SPP1
could be involved in cancer progression have been suggested. The
interaction between osteopontin and its receptors, such as
integrins, avb3 and CD44 (Wang and Denhardt, 2008), and
epidermal growth factor receptor (Rangaswami et al, 2006) can
lead to several signals including upregulation of metalloproteinase
and stimulation of urokinase plasminogen activor. This forms a
basis for metastatic potential by cell migration, cell adhesion and
cell invasiveness (El-Tanani et al, 2006). Osteopontin is also an
antiapoptotic factor and could promote cancer cell metastasis by
preventing programmed cell death (Hsieh et al, 2006). In vitro
studies have suggested a role for osteopontin in melanoma
progression (Philip et al, 2001; Zhou et al, 2005). Very recently a
large immunohistochemical study of 345 melanomas (256 with
SNB status) also reported that increased osteopontin expression
was an independent prognostic marker for melanoma being
associated with SNB positivity, reduced RFS and OS (Rangel
et al, 2008). The same authors have gone on to use osteopontin
protein expression in a multimarker assay including two other
markers not present on our DASL cancer panel (NCOA3, a
member of the steroid receptor coactivator 1 family and RGS1,
a GTPase-activating protein) and found the multimarker index to
be the most significant factor in predicting RFS (Kashani-Sabet
et al, 2009).
This study confirms that SNB is of strong prognostic value in
melanoma patients with HRs for RFS and OS being similar to that
seen in the third interim analysis of the multicentre-selective
lymphadenectomy trial (Morton et al, 2006). SNB results are
reported to provide a more accurate basis for formulating a
prognosis than standard demographic and histopathological
factors (Morton et al, 2006), and it is common in clinical practice
to use SNB results alone to give prognostic information to
melanoma patients. However, our study is the first to show that
prognosis could be better predicted if clinicians used combined
data from the pathology report of the primary tumour in a model
rather than by using the SNB result. Combining SNB status with
those clinico-pathological features, however, does produce a small
further increase in prognostic predictive ability. These data
therefore suggest that although SNB does improve prognostic
estimates, the additional prognostic benefit from the operation is
rather limited. Addition of osteopontin expression into a model
did not further increase prognostic predictive ability once clinico-
pathological features and SNB status had been considered in our
data set.
Limitations of our multicentre study include involvement of
many different pathologists, which can lead to variability in
reporting. Cases were however generally reviewed by the
melanoma multidisciplinary team pathology committee at each
centre. The majority of cases furthermore (83%) originated from
either St George’s Hospital or The Royal Surrey hospital, where
slides are reviewed by the same melanoma team involved in setting
the EORTC guidance for pathological handling and assessment of
sentinel nodes (Cook et al, 2003). However, as explained in the
methodology some histological factors were assumed to be
negative due to absence of reporting. Although a sensitivity
analysis showed quantitavely similar results on the smaller
completed data set, this is a limitation of the study. Patients were
excluded from multivariable analysis due to incompleteness of
pathological data. Owing to the retrospective nature of this study,
the follow-up time was not standardised and varied considerably.
Although the longest period of follow-up did reach 16.75 years, there
were only three patients who had follow-up data over 10 years.
We have used OS rather than melanoma-related survival in the
analyses, as sufficient medical details, to be entirely sure of the
cause of death, were not available in all non-survivors. However,
94% of deaths were known to be melanoma-related. With regard to
gene-expression analysis, a main limitation of the study is the
presence of a limited number of genes on the DASL Cancer Panel.
It was hoped that SNB would have therapeutic value for
melanoma but there is no evidence currently that this is the case
(Morton et al, 2006). The operation is well tolerated by the
majority but is associated with morbidity (Nguyen et al, 2001), so
that an estimate of the likelihood of positivity as reported here may
help some patients to decide, whether to have the procedure or
not. Our study adds further evidence that SNB positivity and
outcome from melanoma is related to clinico-pathological features
of the primary melanoma.
Although the results of SNB did add to prognostic estimates, our
data suggest that it adds relatively little, if all the other clinico-
pathological data are taken into account. The cost/benefit ratio
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Figure 3 Receiver operating characteristic (ROC) analysis of predictors
of relapse for tumour subset group. Purple: clinico-pathological features,
SNB status, SPP1 expression, AUC¼ 72.7%. Dark blue: clinico-pathological
features, SNB status, AUC¼ 72.7%. Green: clinico-pathological features
and SPP1 expression, AUC¼ 67.4%. Red: clinico-pathological features
alone, AUC¼ 66.2%. Light blue: SPP1 expression alone, AUC¼ 59.0%.
Black: SNB status alone, AUC¼ 53.7%.
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from SNB therefore remains to be established. Although estimates
of the predictive value of these models are given here, much larger
pooled data analyses from many centres are necessary to develop
robust predictive and prognostic models to allow use in clinical
practice.
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